Cargando…
(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences
SIMPLE SUMMARY: Multimodal therapy is standard in locally advanced esophageal and gastroesophageal adenocarcinoma. Although substantial differences in incidence and outcome between women and men have been observed, no clear sex-specific treatment guide has been developed. In this summary, we describ...
Autores principales: | Zander, Thomas, Wagner, Anna Dorothea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869883/ https://www.ncbi.nlm.nih.gov/pubmed/35205835 http://dx.doi.org/10.3390/cancers14041088 |
Ejemplares similares
-
Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies
por: Hoefnagel, Sanne J. M., et al.
Publicado: (2022) -
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
por: Tang, Zhaoqing, et al.
Publicado: (2022) -
Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer
por: Chang, Alex Yuang-Chi, et al.
Publicado: (2016) -
Current Status of Intensified Neo-Adjuvant Systemic Therapy in Locally Advanced Rectal Cancer
por: Engels, Benedikt, et al.
Publicado: (2012) -
A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study
por: Mamdani, Hirva, et al.
Publicado: (2021)